CollPlant BiotechnologiesCLGN
Market Cap: $58.6M
About: CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
23% more funds holding
Funds holding: 13 [Q1] → 16 (+3) [Q2]
0.62% more ownership
Funds ownership: 12.37% [Q1] → 12.99% (+0.62%) [Q2]
3% less capital invested
Capital invested by funds: $7.59M [Q1] → $7.39M (-$198K) [Q2]
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 36% 1-year accuracy 49 / 135 met price target | 115%upside $11 | Buy Reiterated | 21 Aug 2024 |
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 173%upside $14 | Buy Maintained | 20 Aug 2024 |
EF Hutton Jason Kolbert 38% 1-year accuracy 10 / 26 met price target | 173%upside $14 | Buy Initiated | 5 Aug 2024 |
Financial journalist opinion
Based on 5 articles about CLGN published over the past 30 days